Page last updated: 2024-09-03

imatinib mesylate and Malignant Melanoma

imatinib mesylate has been researched along with Malignant Melanoma in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (35.56)	29.6817
2010's	51 (56.67)	24.3611
2020's	7 (7.78)	2.80

Authors

Authors	Studies
Berking, C; Erdmann, M; Heppt, MV; Kohl, C; Petzold, A; Steeb, T; Wessely, A	1
Amagai, M; Fukuda, K; Funakoshi, T; Fusumae, T; Hirai, I; Nakamura, Y; Sato, Y; Tanese, K	1
Griewank, K; Hadaschik, E; Jansen, P; Kretz, J; Livingstone, E; Lodde, G; Meier, F; Möller, I; Schadendorf, D; Schlein, C; Song, M; Stadtler, N; Sucker, A; Zaremba, A; Zimmer, L	1
Armstrong, E; Carlino, MS; Carvajal, RD; Johnson, DB; Jung, S; Lee, A; Shoushtari, AN; Sullivan, RJ; Wei, AZ; Ye, F	1
Fang, L; Jia, W; Liu, C; Quan, P; Song, Y; Sun, H; Wang, J	1
Abdou, Y; Ernstoff, MS; Hamad, L; Kapoor, A	1
Amorini, AM; Anfuso, CD; Distefano, A; Giallongo, C; Giurdanella, G; Longo, A; Lupo, G; Salmeri, M; Zanghì, G	1
Beaudoux, O; Criquet, E; Durlach, A; Ehret, M; Franceschi, J; Grange, F; Oudart, JB; Visseaux, L	1
Dummer, R; French, LE; Goldinger, SM; Kränzlin-Stieger, P; Murer, C	1
Boros, LG; Collins, TQ; D'Agostino, DP; Hitendra, P; Meuillet, EJ; Somlyai, G	1
Cho, J; Jang, KT; Kim, JH; Kim, K; Kim, NKD; Kim, ST; Kim, SY; Kim, YJ; Lee, J; Park, W; Sim, MH	1
Honda, T; Kabashima, K; Nomura, M; Otsuka, A; Yamashita, C	1
Bannon, AE; Fleming, WH; Fletcher, JA; Heinrich, MC; Javidi-Sharifi, N; Klug, LR; Musil, LS; Town, A; Tyner, JW; VanSlyke, JK	1
Doi, K; Ishida, Y; Kabashima, K; Komatsu-Fujii, T; Matsumoto, S; Muto, M; Nomura, M; Otsuka, A	1
Bassett, RL; Carapeto, FCL; Eterovic, AK; Grimm, EA; Haydu, LE; Hong, DS; Lazar, AJ; Ma, J; Macedo, MP; McKean, M; Oba, J; Patel, KP; Roth, KG; Siroy, AE; Vo, P; Wang, WL; Woodman, SE	1
Gu, Z; Han, Y; Huang, X; Li, J; Shi, C; Sun, S; Tao, W; Wang, L; Wang, Y; Wu, J; Zhang, Z; Zhou, G; Zhou, R	1
Becker, TM; Kefford, RF; Rizos, H; Todd, JR	1
Colegio, OR; Liu, LS	1
Beadling, C; Collichio, FA; Corless, CL; Demetri, GD; Ernstoff, MS; Fisher, DE; Flaherty, KT; Fletcher, JA; Friedlander, P; Gajewski, TF; Giobbie-Hurder, A; Gonzalez, R; Heinrich, MC; Hodi, FS; Kim, KB; Lawrence, D; Luke, JJ; Marino-Enriquez, A; O'Day, SJ; Van den Abbeele, AD; Weber, JS; Yap, JT; Zhu, M; Zukotynski, KA	1
Carvajal, RD	1
Chi, Z; Cui, C; Dai, J; Guo, J; Kong, Y; Li, S; Lian, B; Liu, S; Mao, L; Sheng, X; Si, L; Xu, X; Yang, R	1
Adenis, A; Amela, EY; Blay, JY; Bui-Nguyen, B; Cassier, PA; Chauzit, E; Clisant, S; Fournier, C; Italiano, A; Molimard, M; Penel, N; Ray-Coquard, I; Tresch-Bruneel, E	1
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Butori, C; Dumaz, N; Giacchero, D; Hofman, P; Hofman, V; Lacour, JP; Segalen, C	1
Ariyan, CE; Bello, DM; Dematteo, RP	1
Calipel, A; De La Fouchardière, A; Landreville, S; Mascarelli, F; Mouriaux, F; Penel, N; Rivoire, M	1
Cooper, ZA; Ferrone, CR; Ferrone, S; Flaherty, KT; Frederick, DT; Kirkwood, JM; Pepe, S; Pepin, D; Sabbatino, F; Scognamiglio, G; Wang, X; Wang, Y; Wargo, JA; Yu, L	1
Al-Refaie, W; Atkins, MB; Parks, K; Rapisuwon, S	1
Agopian, J; Bertucci, F; Chauvot de Beauchêne, I; De Sepulveda, P; Dubreuil, P; Fouet, B; Fournier, B; Mescam-Mancini, L; Panel, N; Tchertanov, L; Tisserand, JC; Vita, M	1
Blank, C; Cornelissen-Steijger, PD; Geukes Foppen, MH; Goding, CR; Graeber, TG; Haanen, J; Hugo, W; Kemper, K; Kong, X; Krijgsman, O; Lo, RS; McDermott, U; Müller, J; Peeper, DS; Possik, PA; Ribas, A; Robert, L; Song, C; Tsoi, J	1
Gajewski, TF; Giobbie-Hurder, A; Gonzalez, R; Hodi, FS; Kim, K; O'Day, S; Van den Abbeele, AD; Weber, J; Yap, JT; Zukotynski, K	1
Amaravadi, RK; Chen, H; Flaherty, KT; Gallagher, M; Hamilton, BK; O'Dwyer, PJ; Rosen, MA; Schuchter, LM; Sehgal, C	1
Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK	1
Avril, MF; Chanal, J; Fourchotte, V; Guegan, S; Kramkimel, N; Moguelet, P	1
Green, G; Moslehi, H; Ortiz-Urda, S; Panzer-Grümayer, R; Posch, C; Rappersberger, K; Sanlorenzo, M; Vujic, I	1
Griewank, KG	1
Ayub, M; Brady, G; Dhomen, N; Dive, C; Fusi, A; Garner, G; Girotti, MR; Gremel, G; Lee, RJ; Lorigan, P; Mandal, AK; Marais, R; Rothwell, DG; Valpione, S; Wallace, A; Wood, S	1
Bastian, BC; Bauer, J; Lutzky, J	1
Clisant, S; Delcambre, C; Durando, X; Fournier, C; Hebbar, M; Isambert, N; Mascarelli, F; Mouriaux, F; Negrier, S; Penel, N	1
Diwan, AH; Ekmekcioglu, S; Ellerhorst, JA; Eton, O; Grimm, EA; Hwang, CS; Hwu, P; Kim, KB; Kinney, SA; Liu, P; Lizee, G; Prieto, VG	1
Bar-Eli, M; Bedikian, AY; Billings, LA; Camacho, LH; Charnsangavej, C; Cormier, JN; Davis, DW; Diwan, AH; Eton, O; Frazier, ML; Gershenwald, JE; Johnson, MM; Kim, KB; Lee, JE; Mansfield, PF; McConkey, DJ; Murgo, AJ; Ng, CS; Papadopoulos, NE; Prieto, VG; Ross, MI	1
Aldrich, W; Dombos, C; Triozzi, PL	1
Corless, CL; Demetri, GD; Fisher, DE; Fletcher, JA; Heinrich, MC; Hodi, FS; Jiang, X; Widlund, HR; Yuen, NK; Zhou, J	1
Becker, JC; Hofmann, UB; Houben, R; Kauczok-Vetter, CS	1
Smalley, KS; Sondak, VK; Weber, JS	1
Plattner, R; Sims, JT	1
Abramson, DH; Daniels, AB	1
Flaherty, KT; Smalley, KS	1
Davies, MA; Fermeglia, M; Gopal, YN; Hwu, P; Ivan, D; Kim, KB; Lazar, AJ; Mills, GB; Papadopoulos, N; Pavan, GM; Podoloff, DA; Pricl, S; Stemke-Hale, K; Trent, JC; Woodman, SE; Yang, D	1
Becker, JC; Houben, R; Pajouh, P; Terheyden, P; Thorns, C; Zillikens, D	1
Gutzmer, R; Kapp, A; Küttler, U; Satzger, I; Schenck, F; Völker, B	1
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A	1
Ando, N; Harada, K; Kawamura, T; Shibagaki, N; Shimada, S; Yamaguchi, M	1
Abdelhay, E; Amarante-Mendes, GP; Binato, R; Bueno-Da-Silva, AE; Castro, FA; Colassanti, MD; De Carvalho, DD; Jacysyn, JF; Leroy, JM; Pereira, WO; Proto-Siqueira, R; Zago, MA; Zanichelli, MA	1
Balagula, Y; Busam, KJ; Carvajal, RD; Myskowski, PL; Wolchok, JD	1
Betz, B; Fullen, D; Lao, CD; McDonnell, K	1
Martin, L	1
Bauer, J; Eigentler, TK; Garbe, C; Held, L; Held, M; Meier, F; Röcken, M	1
Dummer, R; Schoenewolf, NL; Urosevic-Maiwald, M	1
Liang, R; Rubin, BP; Schadendorf, D; Wallace, AR	1
Abourbih, D; Antecka, E; Burnier, MN; Castiglione, E; Di Cesare, S; Fernandes, BF; Isenberg, J; Maloney, S; Martins, C; Neto Belfort, R	1
Antonescu, CR; Bastian, BC; Bouvier, N; Busam, KJ; Cane, L; Carvajal, RD; Chapman, PB; Chmielowski, B; Fusco, A; Lutzky, J; Panageas, KS; Pavlick, AC; Roman, RA; Schwartz, GK; Takebe, N; Teitcher, J; Vemula, S; Wolchok, JD	1
Chi, Z; Corless, CL; Cui, C; Du, N; Flaherty, KT; Guo, J; Han, M; Kong, Y; Li, H; Li, J; Li, L; Li, S; Lin, X; Mao, L; Qin, S; Sheng, X; Si, L; Wang, B; Xu, X; Zhang, X; Zhu, Y	1
Arifi, S; El Mesbahi, O; Errihani, H; Tazi, el M	1
Chi, Z; Cui, C; Dai, J; Flaherty, KT; Guo, J; Kong, Y; Li, S; Sheng, X; Si, L; Xu, X; Yu, W	1
Caltabiano, G; Queirolo, P; Spagnolo, F	1
Tawbi, HA; Tran, A	1
Brown, MC; Casasola, RJ	1
Botella-Estrada, R; Nagore, E; Rubio, L; Soriano, V	1
Dummer, R; Eggmann, N; Goldinger, SM; Rinderknecht, J; Rozati, S	1
Lee, VK; Ong, CW; Pang, B; Tay, CM	1
Bernardeschi, P; De Giorgi, U; Dentico, P; Fiorentini, G; Lanzanova, G; Rossi, S	1
Bar-Eli, M; Eton, O; Heimberger, A; McGary, EC; Mills, L; Onn, A; Shtivelband, M; Thomas, GW	1
Auclair, C; Calipel, A; Glotin, AL; Kherrouche, Z; Lefevre, G; Mascarelli, F; Maurage, CA; Mouriaux, F; Tran, T	1
All-Ericsson, C; Brodin, B; Girnita, L; Larsson, O; Müller-Brunotte, A; Ostman, A; Seregard, S	1
Grossman, D	1
Andreu, EJ; Inoges, S; Lloret, P; Redondo, P	1
Becker, JC; Hildenbrand, R; Hochhaus, A; Keikavoussi, P; La Rosée, P; Paschka, P; Rittgen, W; Schadendorf, D; Sucker, A; Ugurel, S; Zimpfer, A	1
Bakhanashvili, M; Beery, E; Birenbaum, M; Fenig, E; Lahav, M; Luria, D; Nordenberg, J; Reshef, H; Sandbank, J; Uziel, O; Yerushalmi, R	1
Alexis, JB; Lutzky, J; Martinez, AE	1
Beery, E; Fenig, E; Lavie, G; Morgenstern, C; Nordenberg, J; Perlmutter, I; Uziel, O; Weizman, A	1
Atkins, MB; Byrnes, C; Eton, O; Hubbard, F; McDermott, DF; Prieto, V; Sanders, K; Sosman, JA; Wyman, K	1
Baradad, M; Benitez, D; Casanova, JM; Castel, T; Comella, JX; Dolcet, X; Egido, R; Espurz, N; Malvehy, J; Marti, RM; Matias-Guiu, X; Mayorga, ME; Mila, J; Pallares, J; Perez de Santos, AM; Sanchis, D; Velasco, A; Vilella, R	1
Diwan, AH; Eton, O; Gonzalez, C; Ivan, D; Kim, KB; Lacey, C; Niveiro, M; Prieto, VG	1
Bernardeschi, P; Biancalani, M; De Giorgi, U; Dentico, P; Fiorentini, G; Lanzanova, G; Palomba, A; Rossi, S	1
Bastian, BC; Busam, K; Curtin, JA; Pinkel, D	1
Cree, IA; Di Nicolantonio, F; Glaysher, S; Hungerford, JL; Hurren, J; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Whitehouse, PA	1
Avril, MF; Chouaib, S; Faure, F; Hamaï, A; Jalil, A; Kauffmann, A; Larue, L; Lecluse, Y; Mehrpour, M; Meslin, F; Richon, C	1
Becker, JC; Bröcker, EB; Schadendorf, D; Ugurel, S	1
Babchia, N; Calipel, A; Faussat, AM; Mascarelli, F; Mouriaux, F	1
Corless, CL; Demetri, GD; Fisher, DE; Friedlander, P; Heinrich, MC; Hodi, FS; Jagannathan, J; Kruse, A; Mac Rae, S; Van den Abbeele, AD; Velazquez, EF	1

Reviews

14 review(s) available for imatinib mesylate and Malignant Melanoma

Article	Year
c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. European journal of cancer (Oxford, England : 1990), 2021, Volume: 157 Topics: Dasatinib; Exons; Humans; Imatinib Mesylate; Melanoma; Mucous Membrane; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin; Skin Neoplasms; Sunitinib; Sunlight	2021
Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma. Oncotarget, 2017, Jul-25, Volume: 8, Issue:30 Topics: Atorvastatin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Metformin; Phenformin	2017
Molecularly targeted therapies for melanoma. International journal of dermatology, 2013, Volume: 52, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immunotherapy; Indoles; Ipilimumab; Melanoma; Mesylates; Molecular Targeted Therapy; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sulfonamides; Vemurafenib	2013
The GIST of targeted therapy for malignant melanoma. Annals of surgical oncology, 2014, Volume: 21, Issue:6 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Sulfonamides; Vemurafenib	2014
Biomarkers in melanoma. Scandinavian journal of clinical and laboratory investigation. Supplementum, 2016, Volume: 245 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; CTLA-4 Antigen; Early Diagnosis; Humans; Imatinib Mesylate; Melanoma; Melanoma, Cutaneous Malignant; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Prognosis; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Skin Neoplasms	2016
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histology and histopathology, 2009, Volume: 24, Issue:5 Topics: Animals; Benzamides; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Melanoma, Experimental; Mice; Models, Biological; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cell Factor; Uveal Neoplasms	2009
Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:1 Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzamides; Female; Humans; Imatinib Mesylate; Melanoma; Mucous Membrane; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2010
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene, 2011, Jan-13, Volume: 30, Issue:2 Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma; Cell Line; Disease Progression; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Melanoma; Piperazines; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Pyrimidines; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tumor Cells, Cultured; Up-Regulation	2011
[What's new in dermatological treatments?]. Annales de dermatologie et de venereologie, 2010, Volume: 137 Suppl 4 Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab	2010
Oncogenetics of melanoma: basis for molecular diagnostics and therapy. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2011, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; DNA Mutational Analysis; Drugs, Investigational; Humans; Imatinib Mesylate; Melanoma; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Skin Neoplasms	2011
Uveal melanoma. Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Chemotherapy, Adjuvant; Humans; Imatinib Mesylate; Immunotherapy; Ipilimumab; Liver Neoplasms; Melanoma; Piperazines; Pyrimidines; Uveal Neoplasms	2012
A potential role for nilotinib in KIT-mutated melanoma. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:6 Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Melanoma; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2012
KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting. Pathology, 2013, Volume: 45, Issue:2 Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Melanoma; Mutation; Piperazines; Precision Medicine; Proto-Oncogene Proteins c-kit; Pyrimidines; Research Report; Skin Neoplasms	2013
Imatinib mesylate for melanoma: will a new target be revealed? The Journal of investigative dermatology, 2004, Volume: 123, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Melanoma; Piperazines; Pyrimidines; Skin Neoplasms	2004

Trials

14 trial(s) available for imatinib mesylate and Malignant Melanoma

Article	Year
Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol. Medicine, 2021, Dec-10, Volume: 100, Issue:49 Topics: Antibodies, Monoclonal, Humanized; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Imatinib Mesylate; Melanoma; Oncogenes; Proto-Oncogene Proteins c-kit	2021
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chronic Disease; Female; Gene Amplification; GTP Phosphohydrolases; Humans; Imatinib Mesylate; Male; Melanoma; Membrane Proteins; Middle Aged; Mucous Membrane; Mutation; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sunlight; Survival Rate	2013
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. British journal of cancer, 2013, Nov-12, Volume: 109, Issue:10 Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chordoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasms; Piperazines; Pyrimidines; Skin Neoplasms	2013
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer imaging : the official publication of the International Cancer Imaging Society, 2014, Nov-12, Volume: 14 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome	2014
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. The oncologist, 2015, Volume: 20, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged	2015
O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Investigational new drugs, 2008, Volume: 26, Issue:6 Topics: Abdominal Pain; Administration, Oral; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Survival Rate; Uveal Neoplasms	2008
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma research, 2008, Volume: 18, Issue:4 Topics: Benzamides; Extracellular Signal-Regulated MAP Kinases; Humans; Imatinib Mesylate; Melanoma; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Tissue Array Analysis	2008
Phase II trial of imatinib mesylate in patients with metastatic melanoma. British journal of cancer, 2008, Sep-02, Volume: 99, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Disease Progression; DNA Primers; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Skin Neoplasms; Treatment Outcome	2008
Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-01, Volume: 15, Issue:1 Topics: Aged; Aged, 80 and over; Benzamides; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Stem Cell Factor; Up-Regulation; Uveal Neoplasms	2009
KIT as a therapeutic target in metastatic melanoma. JAMA, 2011, Jun-08, Volume: 305, Issue:22 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Survival Analysis; Treatment Outcome	2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-20, Volume: 29, Issue:21 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; China; Disease-Free Survival; Exons; Female; Gene Amplification; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Risk Factors; Skin Neoplasms; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; United States	2011
Lack of clinical efficacy of imatinib in metastatic melanoma. British journal of cancer, 2005, Apr-25, Volume: 92, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Middle Aged; Molecular Sequence Data; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2005
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer, 2006, May-01, Volume: 106, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2006
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial. Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl Topics: Adult; Benzamides; Biomarkers, Tumor; Eye Neoplasms; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines	2003

Other Studies

62 other study(ies) available for imatinib mesylate and Malignant Melanoma

Article	Year
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants. Pigment cell & melanoma research, 2022, Volume: 35, Issue:6 Topics: Adolescent; Adult; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Telomerase; Young Adult	2022
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations. British journal of cancer, 2022, Volume: 127, Issue:9 Topics: Antineoplastic Agents; Genomics; Humans; Imatinib Mesylate; Melanoma; Mutation; Prospective Studies; Proto-Oncogene Proteins c-kit; Retrospective Studies	2022
Construction of Imatinib Controlled Release Film-Forming System Based on Drug Ion-Pair and Oligomeric Ionic Liquids for the Long Local Therapy of Cutaneous Melanoma. AAPS PharmSciTech, 2023, Mar-25, Volume: 24, Issue:4 Topics: Administration, Cutaneous; Animals; Delayed-Action Preparations; Imatinib Mesylate; Ionic Liquids; Melanoma; Melanoma, Cutaneous Malignant; Mice; Oils; Skin; Skin Neoplasms; Spectroscopy, Fourier Transform Infrared	2023
Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report. Medicine, 2019, Volume: 98, Issue:44 Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Treatment Outcome	2019
Uveal Melanoma Cells Elicit Retinal Pericyte Phenotypical and Biochemical Changes in an in Vitro Model of Coculture. International journal of molecular sciences, 2020, Aug-03, Volume: 21, Issue:15 Topics: Becaplermin; Cancer-Associated Fibroblasts; Cell Movement; Cell Proliferation; Coculture Techniques; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Matrix Metalloproteinase 9; Melanoma; Neoplasm Proteins; Pericytes; Receptor, Platelet-Derived Growth Factor beta; Retina; Transforming Growth Factor beta1; Tumor Microenvironment; Uveal Neoplasms; Wound Healing	2020
Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma. Acta dermato-venereologica, 2021, Apr-12, Volume: 101, Issue:4 Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Melanoma; Mutation; Proto-Oncogene Proteins c-kit	2021
Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report. Melanoma research, 2017, Volume: 27, Issue:4 Topics: Female; Humans; Imatinib Mesylate; Ipilimumab; Melanoma; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2017
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:10 Topics: beta Catenin; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Melanoma; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Tumor Cells, Cultured	2017
Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody. Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:3 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Base Sequence; Female; Humans; Imatinib Mesylate; Liver Neoplasms; Lymphatic Metastasis; Melanoma; Mucous Membrane; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins c-kit; Sequence Deletion; Vulvar Neoplasms	2019
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene, 2019, Volume: 38, Issue:8 Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Melanoma; Membrane Proteins; Mice; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-kit; RNA, Small Interfering; Xenograft Model Antitumor Assays	2019
Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab. The Journal of dermatology, 2019, Volume: 46, Issue:6 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Ipilimumab; Melanoma; Nivolumab; Off-Label Use; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Treatment Outcome; Vagina; Vaginal Neoplasms	2019
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. The Journal of investigative dermatology, 2019, Volume: 139, Issue:3 Topics: Antineoplastic Agents; Cancer Care Facilities; Cohort Studies; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Male; Melanoma; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Skin Neoplasms; Survival Analysis; Texas; Treatment Outcome	2019
Repurposing Ponatinib as a Potent Agent against Theranostics, 2019, Volume: 9, Issue:7 Topics: Animals; Antineoplastic Agents; Cohort Studies; Disease Models, Animal; Drug Repositioning; Humans; Imatinib Mesylate; Imidazoles; Male; Melanoma; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridazines; Xenograft Model Antitumor Assays	2019
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment cell & melanoma research, 2013, Volume: 26, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Lentivirus; Melanoma; Mutation; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction	2013
Another option in our KIT of effective therapies for advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26 Topics: Benzamides; Female; Gene Amplification; Humans; Imatinib Mesylate; Male; Melanoma; Mucous Membrane; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sunlight	2013
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24 Topics: Adult; Aged; Benzamides; Benzimidazoles; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2013
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. The Journal of investigative dermatology, 2014, Volume: 134, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Humans; Imatinib Mesylate; Melanoma; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Skin Neoplasms	2014
Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. Clinical & experimental metastasis, 2014, Volume: 31, Issue:5 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Imatinib Mesylate; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stem Cell Factor; Treatment Outcome; Uveal Neoplasms	2014
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget, 2014, Apr-15, Volume: 5, Issue:7 Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; MAP Kinase Signaling System; Melanoma; Mice; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Sulfonamides; Sunitinib; Up-Regulation; Vemurafenib	2014
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Melanoma research, 2014, Volume: 24, Issue:5 Topics: Antineoplastic Agents; Benzamides; Biopsy; DNA Mutational Analysis; Exons; Fatal Outcome; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mucous Membrane; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Stem Cell Factor	2014
Characterization of S628N: a novel KIT mutation found in a metastatic melanoma. JAMA dermatology, 2014, Volume: 150, Issue:12 Topics: Aged, 80 and over; Animals; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Dasatinib; Fatal Outcome; Female; Fibroblasts; Humans; Imatinib Mesylate; Lung Neoplasms; Melanoma; Mutation, Missense; Phosphorylation; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Skin Neoplasms; Spinal Neoplasms; Thiazoles	2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature communications, 2014, Dec-15, Volume: 5 Topics: Aminopyridines; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Imidazoles; Indoles; Melanoma; Mice; Microphthalmia-Associated Transcription Factor; Oximes; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays	2014
A case series of anal melanoma including the results of treatment with imatinib in selected patients. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2016, Volume: 18, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate	2016
Locally Advanced Unresectable Vaginal Melanoma: Response With Anti-Programmed Death Receptor 1. Journal of lower genital tract disease, 2016, Volume: 20, Issue:1 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Immunologic Factors; Immunotherapy; Infusions, Intravenous; Ipilimumab; Melanoma; Programmed Cell Death 1 Receptor; Treatment Outcome; Vaginal Neoplasms	2016
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget, 2016, Jul-19, Volume: 7, Issue:29 Topics: Animals; Cell Movement; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Xenograft Model Antitumor Assays	2016
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:10 Topics: Adult; Aged; Biomarkers, Pharmacological; Carboplatin; Cell-Free Nucleic Acids; DNA, Neoplasm; Exome Sequencing; Female; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Paclitaxel; Precision Medicine; Proto-Oncogene Proteins c-kit; Vaginal Neoplasms	2016
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment cell & melanoma research, 2008, Volume: 21, Issue:4 Topics: Aged; Amino Acid Substitution; Anus Neoplasms; Benzamides; Dose-Response Relationship, Drug; Female; Glutamic Acid; Humans; Imatinib Mesylate; Intestinal Mucosa; Lysine; Melanoma; Neoplasm Metastasis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction	2008
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. Melanoma research, 2008, Volume: 18, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Humans; Imatinib Mesylate; Melanoma; Mice; Piperazines; Pyrimidines; Temozolomide; Uveal Neoplasms; Xenograft Model Antitumor Assays	2008
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23 Topics: Antineoplastic Agents; Base Sequence; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Melanoma; Mucous Membrane; Mutation; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction	2008
MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Melanoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tetrazolium Salts; Thiazoles	2009
c-KIT in uveal melanoma: big fish or red herring? Archives of ophthalmology (Chicago, Ill. : 1960), 2009, Volume: 127, Issue:5 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Melanoma; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Uveal Neoplasms	2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future oncology (London, England), 2009, Volume: 5, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; Melanoma; Mice; Microsomes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Sorafenib	2009
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Molecular cancer therapeutics, 2009, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Humans; Imatinib Mesylate; Melanoma; Models, Molecular; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles	2009
Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. The Journal of investigative dermatology, 2010, Volume: 130, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2010
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British journal of cancer, 2010, Apr-13, Volume: 102, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib	2010
Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. Clinical and experimental dermatology, 2011, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Thumb	2011
Keratoacanthomas associated with imatinib mesylate. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Keratoacanthoma; Male; Melanoma; Piperazines; Pyrimidines; Skin Neoplasms; Treatment Outcome	2011
V559A and N822I double KIT mutant melanoma with predictable response to imatinib? Pigment cell & melanoma research, 2011, Volume: 24, Issue:2 Topics: Aged, 80 and over; Benzamides; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Imatinib Mesylate; Melanoma; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines	2011
Tumour heterogeneity of mucosal melanomas during treatment with imatinib. The British journal of dermatology, 2011, Volume: 165, Issue:2 Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzamides; Fatal Outcome; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Vulvar Neoplasms	2011
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma. Pigment cell & melanoma research, 2011, Volume: 24, Issue:4 Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Enzyme Activation; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mice; Models, Biological; Mutant Proteins; Phosphatidylinositol 3-Kinase; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Signal Transduction; Thiazoles	2011
Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma. Analytical cellular pathology (Amsterdam), 2011, Volume: 34, Issue:3 Topics: Analysis of Variance; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Melanoma; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Rabbits; Time Factors; Tumor Burden; Uveal Neoplasms; Xenograft Model Antitumor Assays	2011
Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report. Journal of gastrointestinal cancer, 2012, Volume: 43 Suppl 1 Topics: Antineoplastic Agents; Anus Neoplasms; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Prognosis; Rectal Neoplasms; Tomography, X-Ray Computed	2012
Major response to everolimus in melanoma with acquired imatinib resistance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-01, Volume: 30, Issue:4 Topics: Benzamides; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Piperazines; Pyrimidines; Sirolimus	2012
Complete response in a melanoma patient treated with imatinib. The Journal of laryngology and otology, 2012, Volume: 126, Issue:6 Topics: Antineoplastic Agents; Benzamides; Exons; Gene Expression; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Nasopharyngeal Neoplasms; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Treatment Outcome	2012
KIT mutations in a series of melanomas and their impact on treatment with imatinib. Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:9 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Pyrimidines; Skin Neoplasms; Treatment Outcome	2012
From chemotherapy to targeted treatment. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; Melanoma; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sulfonamides; Vemurafenib	2012
Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117). Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:5 Topics: Adult; Aged; Benzamides; Eye Neoplasms; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Liposarcoma; Male; Melanoma; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2003
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. The Journal of investigative dermatology, 2004, Volume: 122, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Tumor; Humans; Imatinib Mesylate; Male; Melanoma; Mice; Mice, Nude; Phosphorylation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Xenograft Model Antitumor Assays	2004
Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. The Journal of biological chemistry, 2004, Jul-23, Volume: 279, Issue:30 Topics: Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; DNA Primers; Gene Expression; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mitogens; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Signal Transduction; Stem Cell Factor; Uvea; Uveal Neoplasms	2004
c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Investigative ophthalmology & visual science, 2004, Volume: 45, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Blotting, Western; Cell Division; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Melanoma; Middle Aged; Paraffin Embedding; Phosphorylation; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Skin Neoplasms; Tumor Cells, Cultured; Tyrosine; Uveal Neoplasms	2004
Imatinib mesylate in cutaneous melanoma. The Journal of investigative dermatology, 2004, Volume: 123, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Imatinib Mesylate; Melanoma; Mice; Mice, Inbred C57BL; Piperazines; Pyrimidines; Skin Neoplasms	2004
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. British journal of cancer, 2005, May-23, Volume: 92, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Fanconi Anemia; Humans; Imatinib Mesylate; Melanoma; Mice; Multiple Myeloma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Ewing; Skin Neoplasms; Telomerase; Tumor Cells, Cultured	2005
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma research, 2005, Volume: 15, Issue:4 Topics: Abdominal Neoplasms; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Spinal Neoplasms; Treatment Outcome	2005
Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. International journal of oncology, 2005, Volume: 27, Issue:4 Topics: Adenosine Triphosphate; Animals; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclin D; Cyclin-Dependent Kinase 2; Cyclins; Cytoplasm; Densitometry; DNA Fragmentation; Dopamine Antagonists; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Haloperidol; Humans; Imatinib Mesylate; Ligands; Lipids; Melanoma; Melanoma, Experimental; Mice; Piperazines; Protein Binding; Pyrimidines; Rhodamines; Spectrometry, Fluorescence; Time Factors	2005
Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma research, 2006, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Melanoma; Oncogene Proteins v-abl; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2006
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). Journal of cutaneous pathology, 2006, Volume: 33, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2006
Somatic activation of KIT in distinct subtypes of melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-10, Volume: 24, Issue:26 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Microarray Analysis; Middle Aged; Nucleic Acid Hybridization; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2006
The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Melanoma; Middle Aged; Ovarian Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Skin Neoplasms; Uveal Neoplasms	2006
Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Oncogene, 2006, Dec-07, Volume: 25, Issue:58 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Gene Expression Profiling; Humans; Imatinib Mesylate; Melanoma; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand	2006
Imatinib in melanoma: a selective treatment option based on KIT mutation status? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Melanoma; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2007
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Investigative ophthalmology & visual science, 2008, Volume: 49, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzoquinones; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclins; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Melanoma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Uveal Neoplasms	2008
Major response to imatinib mesylate in KIT-mutated melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12 Topics: Aged; Anastomosis, Surgical; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Melanoma; Mutation; Neoplasm Recurrence, Local; Neoplasm Seeding; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms	2008